104 related articles for article (PubMed ID: 38747001)
1. RPGRIP1L as a new biomarker for prognosis and tumor immune of breast cancer.
Yi J; Liu L; Chen Y; Ding T; Fan P; Yu J; Zeng J
FASEB J; 2024 May; 38(9):e23624. PubMed ID: 38747001
[TBL] [Abstract][Full Text] [Related]
2. Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer.
Chen F; Han B; Meng Y; Han Y; Liu B; Zhang B; Chang Y; Cao P; Fan Y; Tan K
Aging (Albany NY); 2021 Aug; 13(16):20438-20467. PubMed ID: 34413268
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.
Li HN; Li XR; Lv ZT; Cai MM; Wang G; Yang ZF
Cancer Med; 2020 Dec; 9(24):9554-9570. PubMed ID: 33058542
[TBL] [Abstract][Full Text] [Related]
4. GPI: An indicator for immune infiltrates and prognosis of human breast cancer from a comprehensive analysis.
Zeng J; Yi J; Tan S; Zeng Y; Zou L; Zhang C; Liu L; Yi P; Fan P; Yu J
Front Endocrinol (Lausanne); 2022; 13():995972. PubMed ID: 36246907
[TBL] [Abstract][Full Text] [Related]
5. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Rody A; Holtrich U; Pusztai L; Liedtke C; Gaetje R; Ruckhaeberle E; Solbach C; Hanker L; Ahr A; Metzler D; Engels K; Karn T; Kaufmann M
Breast Cancer Res; 2009; 11(2):R15. PubMed ID: 19272155
[TBL] [Abstract][Full Text] [Related]
6. High expression of transmembrane P24 trafficking protein 9 predicts poor prognosis in breast carcinoma.
Ju G; Xu C; Zeng K; Zhou T; Zang L
Bioengineered; 2021 Dec; 12(1):8965-8979. PubMed ID: 34635011
[TBL] [Abstract][Full Text] [Related]
7. Identification of LCN1 as a Potential Biomarker for Breast Cancer by Bioinformatic Analysis.
Yang Y; Li F; Luo X; Jia B; Zhao X; Liu B; Gao R; Yang L; Wei W; He J
DNA Cell Biol; 2019 Oct; 38(10):1088-1099. PubMed ID: 31424267
[TBL] [Abstract][Full Text] [Related]
8. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.
Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K
Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497
[TBL] [Abstract][Full Text] [Related]
9. High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.
Li F; Sun H; Li Y; Bai X; Dong X; Zhao N; Meng J; Sun B; Zhang D
BMC Cancer; 2021 Dec; 21(1):1305. PubMed ID: 34876062
[TBL] [Abstract][Full Text] [Related]
10. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
Li D; Zhao W; Zhang X; Lv H; Li C; Sun L
Clin Epigenetics; 2021 May; 13(1):112. PubMed ID: 34001208
[TBL] [Abstract][Full Text] [Related]
11. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis reveals a prognostic and therapeutic biomarker CD3D in the breast carcinoma microenvironment.
Zhu Z; Ye W; Wu X; Lin S; Xu J; Li L; Li J; Wang H; Huang Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33350431
[TBL] [Abstract][Full Text] [Related]
13. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2 inhibits activating transcription factor 7 to promote breast cancer cell migration by activating histone lysine demethylase 1.
Lin J; Mao H; Ji Z; Lin W; Wang T
J Cancer Res Ther; 2021 Nov; 17(5):1192-1201. PubMed ID: 34850767
[TBL] [Abstract][Full Text] [Related]
15. Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer.
Han B; Zhen F; Zheng XS; Hu J; Chen XS
BMC Cancer; 2022 Mar; 22(1):297. PubMed ID: 35313846
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer.
Liu X; Wang W; Chen B; Wang S
Aging (Albany NY); 2024 Apr; 16(8):7188-7216. PubMed ID: 38643462
[TBL] [Abstract][Full Text] [Related]
17. ACE2 maybe serve as a prognostic biomarker in breast invasive carcinoma.
Ling J; Peng N; Luo L
J Clin Lab Anal; 2022 Jun; 36(6):e24362. PubMed ID: 35373393
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer.
Chen F; Fan Y; Hou J; Liu B; Zhang B; Shang Y; Chang Y; Cao P; Tan K
Aging (Albany NY); 2021 Sep; 13(17):21671-21699. PubMed ID: 34518441
[TBL] [Abstract][Full Text] [Related]
19. KRAS expression is a prognostic indicator and associated with immune infiltration in breast cancer.
Liang H; Zhou G; Lv L; Lu J; Peng J
Breast Cancer; 2021 Mar; 28(2):379-386. PubMed ID: 33067762
[TBL] [Abstract][Full Text] [Related]
20. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
